patient dosing system News
-
Genenta Data Presentation at AACR to Describe On-Target Biological Activity of Temferon™ in Unmethylated Glioblastoma Multiforme
Genenta Science (NASDAQ: GNTA), a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene therapy for cancer, will present clinical data from its Phase 1/2a dose-escalation study of its clinical-stage candidate Temferon™ in patients with glioblastoma multiforme (GBM) who have an unmthylated MGMT gene promotor (uMGMT-GBM) at the ...
-
Novel Drug Delivery System Unveiled: CD Formulation Launches Oral Thin Films Technology
In a groundbreaking development in the field of pharmaceuticals, CD Formulation, a prominent drug formulation company, has announced the launch of Oral Thin Film Technology. This cutting-edge drug delivery system is poised to revolutionize medication administration, offering patients a more convenient and effective treatment method. Oral Thin Film Technology is a user-friendly drug delivery ...
-
Gesynta Pharma initiates Phase II study of its first-in-class drug candidate GS-248 in patients with systemic sclerosis
Gesynta Pharma AB today announced that the first patients have been dosed in a Phase II study of its oral drug candidate GS-248 in patients with systemic sclerosis - a debilitating autoimmune disease that causes serious damage to the microvasculature. This proof-of-concept study will investigate the safety of GS-248 and its efficacy on Raynaud's phenomenon and peripheral blood flow in this ...
-
Osprey Medical, Inc. Awarded Premier Purchasing Agreement for DyeVert™ PLUS Contrast Reduction System
Osprey Medical (ASX: OSP) today is announcing that its DyeVert Plus Contrast Reduction System was awarded a group purchasing agreement as a Technology Breakthroughs award with Premier Inc. (Premier), a leading healthcare improvement company. Osprey Medical’s DyeVert Plus System is the only technology cleared by the U. S. Food & Drug Administration for contrast reduction and real-time ...
-
GPB Scientific Announces Initial Availability of Advanced Cell Separation Platform; Name Change to Curate Biosciences
GPB Scientific, Inc. has launched its go-to-market activities for the transformational Curate® Cell Processing System to streamline the manufacture of cell therapies, making them economically and reliably available to the largest number of patients. The company's advanced cell separation platform is in evaluations at select biopharmas, contract manufacturers, and academic centers ahead of the ...
-
Analyzing Delivery Systems: CD Formulation Introduces In Vitro Testing to Measure Microsphere and Microneedle Release
Researchers and scientists at CD Formulation, a leading pharmaceutical company, have achieved a breakthrough in drug delivery systems with the introduction of an innovative in vitro testing method. This method allows for the precise measurement of release rates for microspheres and microneedles, providing valuable insights for drug formulation and optimizing therapeutic outcomes. By incorporating ...
-
Blueberry Therapeutics announces extension of its Series B round with investment from Medical Incubator Japan and US Dermatology Syndicate
Blueberry Therapeutics Limited would like to announce that it has completed a £3.6m extension to the previously successful Series B Fundraising of £10.8m. This investment is from a Japanese investor, Medical Incubator Japan (MIJ) and a private syndicate of US Board Certified Dermatologists led by Dr Omar Ibrahimi of Stamford, CT. Blueberry Therapeutics is a dermatology-focused drug ...
-
Osprey Introduces DyeVert PLUS at TCT
Osprey Medical (ASX:OSP) is pleased to announce the expansion of its portfolio with introduction of the DyeVert™ PLUS Contrast Modulation/Monitoring System. This new platform integrates the current DyeVert technology with substantial patient management and monitoring capabilities. The system has received European CE Mark and FDA clearance is pending. The Company anticipates US availability ...
-
BioCardia Receives FDA Breakthrough Device Designation for CardiAMP Cell Therapy System for Heart Failure
BioCardia®, Inc. (Nasdaq: BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for the CardiAMP® Cell Therapy System for the treatment of heart failure. It is believed to be the first cardiac cell therapy to ...
-
People who have recovered from COVID-19 Can Now Donate their Convalescent Plasma in select Grifols U.S. Plasma Donor Centers
Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company with a track record of more than 100 years and a recognized leader in the development and production of plasma-derived medicines, today announced it has begun identifying, screening and selecting volunteer donors who have recovered from COVID-19 to donate their plasma in select U.S. cities. The plasma will be used to produce ...
-
Curate Biosciences and City of Hope Evaluate Innovative Cell Separation for HIV CAR-T Cell Therapy Production
Curate Biosciences, a key enabling technology company for cell therapy manufacturing, announced the first outcome of its Technology Access Program, which is dedicated to converting research into real-world treatments and cures as rapidly as possible. City of Hope, one of the largest cancer research and treatment organizations in the United States, has evaluated the Curate® Cell Processing ...
-
Immatics Reports Clinical Responses across Multiple Solid Tumor Types in Ongoing ACTengine® IMA203 Phase 1a Trial Targeting PRAME
Company to host conference call on Tuesday, November 9 at 8:30 am EST Dose escalation for cell therapy candidate ACTengine® IMA203 ongoing; dose level 3 completed at doses below 1 billion transduced cells Objective responses (RECIST 1.1) observed in 8/16 patients (50%) across multiple solid cancer types, with 8/13 responders (62%) treated at dose levels 2 and 3 High T cell engraftment ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you